FTC Dems’ view on pharma deal raises eyebrows
The Federal Trade Commission’s approval of Bristol-Myers Squibb/Celgene last week drew opposition from its Democratic members, worrying some antitrust lawyers about an ideological divide but winning praise from other competition experts.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10